BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
BeOne Medicines will present data across its solid tumor portfolio at the ESMO 2026 Congress in Madrid on October 23-27, including a late-breaking rapid oral on TEVIMBRA plus ZIIHERA in HER2+ gastroesophageal adenocarcinoma (second interim analysis of Phase 3 HERIZON-GEA-01). Priority pipeline data include updated Phase 1 results for the GPC3x4-1BB bispecific in advanced HCC and first-in-human reads for a CEA-targeting ADC in NSCLC and a brain-penetrant PRMT5 inhibitor in MTAP-deleted tumors. A trial-in-progress abstract covers KANDELA-302, a global Phase 3 study of the CDK4 inhibitor BGB-43395 in first-line HR+/HER2- metastatic breast cancer.
Key figures
- Drug Name
- TEVIMBRA (tislelizumab); pipeline assets BGB-B2033, BG-C477, BGB-58067, BGB-43395
- Tevimbra trials
- 71 trials including 21 registration-enabling studies
- Esmo congress dates
- October 23-27, 2026, Madrid
- Tevimbra enrolled patients
- almost 15,000
- Tevimbra patients treated globally
- more than 2.2 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.